Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab Combinations in Advanced Solid Tumors
NCT03459222Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2018
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
A Phase 2 trial of relatlimab in solid tumor (advanced stage), sponsored by Bristol Myers Squibb. Started May 2018; status: completed.
02
Drugs
relatlimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03459222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03459222.